<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vestib</journal-id><journal-title-group><journal-title xml:lang="ru">Известия Национальной  академии наук Беларуси. Серия биологических наук</journal-title><trans-title-group xml:lang="en"><trans-title>Proceedings of the National Academy of Sciences of Belarus, Biological Series</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1029-8940</issn><issn pub-type="epub">2524-230X</issn><publisher><publisher-name>The Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29235/1029-8940-2024-69-3-217-223</article-id><article-id custom-type="elpub" pub-id-type="custom">vestib-927</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Особенности функционирования дофаминергической и серотонинергической нейромедиаторных систем некоторых отделов головного мозга крыс при введении препаратов AZT (зидовудин) и S-аденозил-L-метионин</article-title><trans-title-group xml:lang="en"><trans-title>Features of the functioning of dopaminergic and serotonergic neurotransmitter systems of some parts of the rat brain after AZT (zidovudine) and S-adenosyl-L-methionine drugs administration</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Филина</surname><given-names>Н. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Filina</surname><given-names>N. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Филина Нина Ивановна – ст. преподаватель.</p><p>ул. Горького, 80, 230009, Гродно</p></bio><bio xml:lang="en"><p>Nina I. Filina - Senior lecturer, Grodno State Medical University.</p><p>80, Gorky Str., 230009, Grodno</p></bio><email xlink:type="simple">nina-filina-2017@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8518-2450</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Курбат</surname><given-names>М. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Kurbat</surname><given-names>M. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Курбат Михаил Николаевич -канд. мед. наук, доцент, заведующий лабораторией.</p><p>ул. Горького, 80, 230009, Гродно</p></bio><bio xml:lang="en"><p>Mikhail N. Kurbat - Ph. D. (Med.), Associate Professor, Head of the Laboratory, Grodno State Medical University.</p><p>80, Gorky Str., 230009, Grodno</p></bio><email xlink:type="simple">vwmisha@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Гродненский государственный медицинский университет</institution></aff><aff xml:lang="en"><institution>Grodno State Medical University</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>31</day><month>07</month><year>2024</year></pub-date><volume>69</volume><issue>3</issue><fpage>217</fpage><lpage>223</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Филина Н.И., Курбат М.Н., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Филина Н.И., Курбат М.Н.</copyright-holder><copyright-holder xml:lang="en">Filina N.I., Kurbat M.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://vestibio.belnauka.by/jour/article/view/927">https://vestibio.belnauka.by/jour/article/view/927</self-uri><abstract><p>Известно, что антиретровирусный препарат зидовудин (AZT), зарекомендовавший себя не только в лечении ВИЧ-инфекции, оказывает побочные эффекты на центральную нервную систему. В основе патогенеза всех психопатологических симптомов лежат процессы активации и торможения нейромедиаторных систем, поэтому целью данной работы являлось сравнение показателей, характеризующих основные моноаминергические системы головного мозга крыс, включая уровни аминокислот-предшественников и метаболитов, в различных его отделах при воздействии лекарственных средств зидовудин (AZT) и гептрал (SAM) по отдельности и в комбинации и оценка возможного корригирующего эффекта S-аденозилметионина в условиях эксперимента. Последний обладает потен­циальным нейропротекторным действием, уменьшая выраженность когнитивных нарушений при старении мозга, что связано с ингибированием окислительного стресса и нейровоспаления. Результаты эксперимента показали, что эффект AZT в большей степени проявляется на функционировании дофаминергической нейромедиаторной системы гипоталамуса (повышение уровня дофамина), а также стриатума и ствола головного мозга крыс (снижение содержания нейромедиатора), при этом увеличение концентрации серотонина наблюдается только в стволе. Применение SAM на фоне AZT приводило к нормализации содержания дофамина в гипоталамусе, стриатуме и стволе головного мозга крыс, а применение серотонина нормализовало его уровень в стволе, что свидетельствует о корригирующем эффекте препарата в отношении исследуемых показателей. При комбинированном применении SAM и AZT показатели концентрации серотонина во всех изученных отделах головного мозга крыс увеличивались и были близки к их значениям в группе животных, получавших только SAM.</p></abstract><trans-abstract xml:lang="en"><p>Zidovudine (AZT) is an antiretroviral drug that has proven itself not only in treating HIV infection, but is associated with side effects on the central nervous system. All psychopathological symptoms are based on the processes of activation and inhibition of neurotransmitter systems, therefore, the purpose of this work was a comparative study of indi­cators characterizing the main monoaminergic systems of the brain of rats, including levels of amino acids precursors and metabolites, in different parts of the brain of rats when exposed to drugs zidovudine (AZT) and heptral (SAM) individually and in combination; to evaluate a possible corrective effect of S-adenosyl-L-methionine under experimental conditions. The latter has a potential neuroprotective effect on improving cognitive impairment during brain aging, which is associated with inhibiting oxidative stress and neuroinflammation. The results of the experiment showed that the effect of AZT is reflected to a greater extent on the functioning of the dopaminergic neurotransmitter system of the hypothalamus (increased dopamine levels), the striatum and midbrain of rats (decreased neurotransmitter content), an increase in serotonin concentration was noted only in the midbrain. The use of SAM against the background of AZT led to normalizing the dopamine content in the hypothalamus, striatum and brain stem of rats, serotonin - in the stem, which indicates the corrective effect of the drug on the studied neurotransmitter systems. The combined use of SAM and AZT leads to increasing serotonin concentrations in all studied parts of the brain of rats and are close to the values in the group of animals treated only with SAM.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>AZT</kwd><kwd>SAM</kwd><kwd>дофамин</kwd><kwd>головной мозг крыс</kwd><kwd>серотонин</kwd><kwd>нейромедиаторная система</kwd><kwd>корригирующий эффект</kwd></kwd-group><kwd-group xml:lang="en"><kwd>AZT</kwd><kwd>SAM</kwd><kwd>dopamine</kwd><kwd>brain of rats</kwd><kwd>serotonin</kwd><kwd>neurotransmitter system</kwd><kwd>corrective effect</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Rubin, L. H. HIV, depression and cognitive impairment in the era of effective antiretroviral therapy / L. H. Rubin, P. M. Maki // Curr. HIV/AIDS Rep. - 2019. - Vol. 16, N 1. - P 82-95. https://doi.org/10.1007/s11904-019-00421-0</mixed-citation><mixed-citation xml:lang="en">Rubin L. H., Maki P. M. HIV, depression and cognitive impairment in the era of effective antiretroviral therapy. Current HIV/AIDS Report, 2019, vol. 16, no. 1, pp. 82-95. https://doi.org/10.1007/s11904-019-00421-0</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Schneider, M. A. Combination of antiretroviral drugs Zidovudine and Efavirenz impairs tumor growths in a mouse model of cancer / M. A. Schneider, A. A. Buzdin // Viruses. - 2021.- Vol. 13, N 12. - P. 2396. https://doi.org/10.3390/v13122396</mixed-citation><mixed-citation xml:lang="en">Schneider M. A., Buzdin A. A. Combination of antiretroviral drugs Zidovudine and Efavirenz impairs tumor growths in a mouse model of cancer. Viruses, 2021, vol. 13, no. 12, p. 2396. https://doi.org/10.3390/v13122396</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Shafiee, A. Alfa based regimens for the treatment of adult T-cell leukemia/lymphoma (ATLL): a systematic review and meta-analysis / A. Shafiee, N. Seighali // Virol. J. - 2023. - Vol. 20. - P. 118. https://doi.org/10.1186/s12985-023-02077-0</mixed-citation><mixed-citation xml:lang="en">Shafiee A., Seighali N. Alfa based regimens for the treatment of adult T-cell leukemia/lymphoma (ATLL): a systematic review and meta-analysis. Virological Journal, 2023, vol. 20, p. 118. https://doi.org/10.1186/s12985-023-02077-0</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Сукиасян, С. Г. Мозг и психика: биологические основы психиатрии / С. Г. Сукиасян // Sci. Eur. - 2022. - Т. 90. - С. 42-53.</mixed-citation><mixed-citation xml:lang="en">Sukiasyan S. G. Brain and mentality: biological foundations of psychiatry. Sciences of Europe, 2022, vol. 90, pp. 42-53 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Cerebrospinal fluid levels of 5-HIAA and dopamine in people with HIV and depression / R. Fu [et al.] // J. Neurovirol. - 2023. - Vol. 29. - P. 440-448. https://doi.org/10.1007/s13365-023-01142-2</mixed-citation><mixed-citation xml:lang="en">Fu R., Jinnah H., Mckay J. L., Miller A. H., Felger J. C., Farber E. W., Sharma S., Whicker N. Cerebrospinal fluid levels of 5-HIAA and dopamine in people with HIV and depression. Journal of Neurovirology, 2023, vol. 29, pp. 440-448. https://doi.org/10.1007/s13365-023-01142-2</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">A comprehensive review on the efficacy of S-adenosyl-L-methionine in major depressive disorder / D. De Berardis [et al.] // CNS Neurol. Disorder Drug Targets. - 2016. - Vol. 15, N 1. - P. 35-44. https://doi.org/10.2174/1871527314666150821103825</mixed-citation><mixed-citation xml:lang="en">De Berardis D., Orsolini L., Serroni N., Girinelli G., Iasevoli F., Tomasetti C. A comprehensive review on the efficacy of S-adenosyl-L-methionine in major depressive disorder. CNS Neurological Disorder Drug Targets, 2016, vol. 15, no. 1, pp. 35-44. https://doi.org/10.2174/1871527314666150821103825</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">S-adenosylmethionine improves cognitive impairment in D-galactose-induced brain aging by inhibiting oxidative stress and neuroinflammation / Y. Zhang [et al.] // J. Chem. Neuroanat. - 2023. - Vol. 128. - P. 102232. https://doi.org/10.1016/j.jchemneu.2023.102232</mixed-citation><mixed-citation xml:lang="en">Zhang Y., Ma R., Deng Q., Wang W., Cao Ch., Yu Ch. S-adenosylmethionine improves cognitive impairment in D-galactose-induced brain aging by inhibiting oxidative stress and neuroinflammation. Journal of Chemical Neuroanatomy, 2023, vol. 128, p. 102232. https://doi.org/10.1016/j.jchemneu.2023.102232</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Otero-Losada, M. E. Acute changes in 5-HT metabolism after S-adenosyl-L-methionine administration / M. E. Otero- Losada, M. C. Rubio // Gen. Pharmacol. - 1989. - Vol. 20, N 4. - P. 403-406. https://doi.org/10.1016/0306-3623(89)90186-9</mixed-citation><mixed-citation xml:lang="en">Otero-Losada M. E., Rubio M. C. Acute changes in 5-HT metabolism after S-adenosyl-L-methionine administration. General Pharmacology, 1989, vol. 20, no. 4, pp. 403-406. https://doi.org/10.1016/0306-3623(89)90186-9</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">S-Adenosylmethionine (SAMe) for neuropsychiatric disorders: A clinical-oriented review of research / A. Sharma [et al.] // J. Clin. Psychiatry. - 2017. - Vol. 78, N 6. - P. 656-667. https://doi.org/10.4088/jcp.16r11113</mixed-citation><mixed-citation xml:lang="en">Sharma A., Gerbarg P., Bottiglieri T., Massoumi L., Carpenter L., Lavretsky H., Muskin Ph., Brown R., Mischoulon D. S-Adenosylmethionine (SAMe) for neuropsychiatric disorders: A clinical-oriented review of research. Journal of Clinical Psychiatry, 2017, vol. 78, no. 6, pp. 656-667. https://doi.org/10.4088/jcp.16r11113</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Дорошенко, Е. М. Биогенные моноамины, их предшественники и метаболиты в мозге крыс при экспериментальной недостаточности кровообращения / Е. М. Дорошенко, В. В. Лелевич // Нейрохимия. - 2020. - Т. 37, № 3. - С. 240-248.</mixed-citation><mixed-citation xml:lang="en">Doroshenko E. M., Lelevich V. V. Biogenic monoamines, their precursors and metabolites in the brain of rats with experimental circulatory insufficiency. Neirokhimiya [Neurochemistry], 2020, vol. 37, no. 3, pp. 240-248 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Zidovudine and Lamivudine as potential agents to combat HIV-associated neurocognitive disorder / S. Mdanda [et al.] // Drug Dev. Tech. - 2019.- Vol. 17, N 7. - P. 322-329. https://doi.org/10.1089/adt.2019.941</mixed-citation><mixed-citation xml:lang="en">Mdanda S., Ntshangase S., Singh S. D., Naicker T., Kruger H. G., Baijnath S., Govender Th. Zidovudine and Lamivudine as potential agents to combat HIV-associated neurocognitive disorder. Drug Development Technologies, 2019, vol. 17, no. 7, pp. 322-329. https://doi.org/10.1089/adt.2019.941</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Gurevich, E. V. G protein-coupled receptor kinases as regulators of dopamine receptor functions / E. V. Gurevich, R. R. Gainetdinov, V. V. Gurevich // Pharmacol. Res. - 2016. - Vol. 111. - P. 1-16. https://doi.org/10.1016/j.phrs.2016.05.010</mixed-citation><mixed-citation xml:lang="en">Gurevich E. V., Gainetdinov R. R., Gurevich V. V. G protein-coupled receptor kinases as regulators of dopamine receptor functions. Pharmacology Resourse, 2016, vol. 111, pp. 1-16. https://doi.org/10.1016/j.phrs.2016.05.010</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">The HIV antiretroviral drug efavirenz has LSD-like properties / B. Michael [et al.] // Neuropsychopharmacology. - 2013. - Vol. 38, N 12. - P. 2373-2384. https://doi.org/10.1038/npp.2013.135</mixed-citation><mixed-citation xml:lang="en">Gatch M. B., Kozlenkov A., Huang R., Yang W., Nguyen J., Gonzalez-Maeso J., Rice K. C., France Ch., Dillon G. The HIV antiretroviral drug efavirenz has LSD-like properties. Neuropsychopharmacology, 2013, vol. 38, no. 12, pp. 2373-2384. https://doi.org/10.1038/npp.2013.135</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Bertrand, L. Cerebral vascular toxicity of antiretroviral therapy / L. Bertrand, M. Velichkovska, M. Toborek // J. Neuroimmune Pharmacol. - 2021. - Vol. 16, N 1. - P. 74-89. https://doi.org/10.1007/s11481-019-09858-x</mixed-citation><mixed-citation xml:lang="en">Bertrand L., Velichkovska M., Tobore M. Cerebral vascular toxicity of antiretroviral therapy. Journal of Neuroimmune Pharmacology, 2021, vol. 16, no. 1, pp. 74-89. https://doi.org/10.1007/s11481-019-09858-x</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
